Water-soluble biomolecule glass microneedle and method for preparing same
By preparing biomolecular glass soluble microneedles, the problems of limited glass transition temperature range and insufficient glass formation ability in traditional microneedle technology are solved, efficient biomolecule release and skin penetration are achieved, the process is simplified and suitable for industrial production .
Patent Information
- Application Number
- PCT/CN2023/092309
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-05
- Publication Date
- 2024-11-14
AI Technical Summary
The existing microneedle technology has problems with limited glass transition temperature (Tg) range, insufficient glass formation capacity (GFA) and difficulty in achieving efficient biomolecular release in terms of skin transdermal administration, and the traditional process is complex and not environmentally friendly.
Biomolecular glass soluble microneedles are used to prepare biomolecular glass by hydrothermal method, and combined with microneedle preparation processes such as casting, stretching, atomization spraying or 3D printing to prepare microneedles with excellent mechanical properties and processing properties. Array, microneedles with needle tip hardness greater than 50MPa and elastic modulus greater than 1Gpa, use biomolecules and polymer auxiliary materials to form a substrate to achieve rapid release and high bioavailability.
The photostability and thermal stability of biomolecular glass microneedles are achieved, the preparation process is simplified, the bioavailability of biomolecules is improved, and it is suitable for industrial production, with good skin penetration and drug release effect.
Smart Images

Figure CN2023092309_14112024_PF_FP_ABST
Abstract
Description
Water-soluble biomolecule glass microneedle and preparation method Technical Field
[0001] The present invention relates to a biomolecule glass soluble microneedle, a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations and preparation methods thereof. Background Art
[0002] Transdermal absorption and drug delivery technologies have a long history, dating back to ancient Rome. Technological advancements in this field continue to evolve, with applications such as chemical permeability enhancers, iontophoresis, microdermabrasion, ultrasonic cavitation, and microneedling. In recent years, microneedle technology has been recognized as one of the top ten emerging technologies of 2020 by both Scientific American and the World Economic Forum, due to its unique advantages and potential applications.
[0003] Microneedles are micron-sized (<1000 μm in length) conical, tapered, or multifaceted puncturing protrusions that offer numerous advantages for intradermal drug delivery. The application of microneedles creates temporary channels in the outer layer of the skin, thereby bypassing the barrier function and allowing the delivery of various bioactive molecules, particularly biomacromolecules such as peptides, nucleic acids, proteins, or stem cells, that would otherwise be unable to be delivered transdermally. The short axis of the microneedle is long enough to penetrate the stratum corneum but not the underlying nerve endings; therefore, microneedle application is essentially painless, improving patient compliance, especially for those with needle phobia.
[0004] Microneedles are classified based on their dissolution properties after insertion into the stratum corneum, either dissolving or non-dissolving. Non-dissolving microneedles are often made of metal, single-crystal silicon, or cross-linked polymers. To facilitate transdermal bioactive molecules, they must be coated or applied after microneedle removal to allow the molecules to pass through the skin pores created by the microneedles. The micropores in the skin begin to heal upon microneedle removal, and the duration of the microneedle pores is limited by the skin's natural repair process, making it difficult to further improve the overall transdermal absorption efficiency of bioactive molecules. Furthermore, there is the risk of the needle tip breaking and becoming lodged in the skin. Dissolving microneedles are often composed of biocompatible polymers, including water-soluble polymers such as hyaluronic acid, chitosan, polyvinyl alcohol, chondroitin sulfate, polyvinyl pyrrolidone, trehalose, dextran, maltose, sucrose, and carboxymethyl cellulose. These polymer tip matrices can be loaded with bioactive molecules, increasing the drug loading capacity of the microneedles, making them the most promising type of microneedle. For example: In the reference document (Chinese patent CN104027324B), a soluble microneedle vaccine patch suitable for transdermal administration of vaccines is provided, which is made of a water-soluble polymer material as a matrix material, and realizes the effective combined use of vaccines and adjuvants in soluble microneedles, thereby improving the effect of Th1 type immune response and obtaining a relatively balanced Th1 and Th2 type immune response. U.S. Patent US2023015942 A1 discloses a microneedle delivery device with a detachable mixed microneedle reservoir for delivering mesenchymal stem cells to various tissues and organs for tissue regeneration. Invention patent CN 110769812 A describes a microneedle system based on polyvinylpyrrolidone (PVP) loading and releasing glucagon-like peptide analogs. U.S. Patent US9320878B2 discloses a polymer microneedle patch that can achieve transdermal controlled release of hydrophilic macromolecules such as proteins, peptides, DNA, RNA and other drugs.
[0005] The common feature of the above-mentioned soluble microneedles and / or microneedle devices for delivering biomolecules is that the needle body of the microneedle is mainly composed of inactive excipient components, which only serve as carriers of biomolecules or plasticizers for the microneedles. As a result, the current application of soluble microneedles still faces some problems that need to be solved: on the one hand, before clinical application, it is necessary to study the metabolism and elimination pathways of the components that can be dissolved in the skin to determine the biosafety of the material, which will inevitably delay the commercialization process. Therefore, the microneedle devices currently in clinical trials and clinical approvals are still mainly insoluble microneedles. On the other hand, in microneedle applications, the existing polymer needle tips may partially deposit in the skin after dissolving in the body, forming granulations, local erythema, or accumulating in organs in the body, resulting in material accumulation or material metabolic burden. In addition, due to their small size, microneedles can only deliver a limited number of active molecules, limiting their application when large doses or continuous release of bioactive molecules are required.
[0006] In summary, the development of soluble microneedles that are independent of excipients such as water-soluble polymers and are composed of bioactive molecules themselves can expand the dosage and safety of microneedles, laying the foundation for expanding the clinical application of soluble microneedles.
[0007] Summary of the Invention
[0008] To address the challenges presented in the prior art, the present invention provides biomolecular glass soluble microneedles and methods for their preparation. We successfully provide a universal strategy for incorporating multiple non-covalent bonds and trace amounts of solvent into a processable biomolecular glass, which can then be used to prepare biomolecular glass microneedles. Through the aforementioned kinetically stabilized techniques, the resulting biomolecular glass network exhibits extreme compressibility, high mechanical strength, and no observed fracture at 90% strain.
[0009] Existing literature indicates that the salt form, crystal form, crystalline state, and crystallization process of a raw drug significantly impact its stability, solubility, dissolution rate, bioavailability, in vivo absorption, and distribution properties. Therefore, raw drug substances require various solid-state developments to improve their properties, such as intrinsic dissolution, solubility, hygroscopicity, and stability. CN113754556B and CN114014908A disclose methods for preparing amino acid-based biomolecule glasses and cyclic peptide glasses, as well as pharmaceutical composition glasses containing cyclic peptides, via a melt-quenching process, respectively, expanding the application range of these biomolecules.
[0010] The microneedle tips of the present invention are composed of biomolecular glass, which not only allows for smooth and complete penetration of the skin and mucous membranes, but also regulates the rate of release of bioactive molecules, effectively increasing the dissolution rate of bioactive molecules and improving drug bioavailability. The microneedle tips are composed entirely of biomolecules and can be fully absorbed by the body after drug administration, without increasing the body's metabolic burden. The microneedles of the present invention have a large bioactive molecule loading capacity and a simple and rapid preparation method, making them suitable for industrial production.
[0011] A first aspect: providing a biomolecule glass soluble microneedle, wherein the microneedle comprises a microneedle array and a substrate;
[0012] wherein at least a portion of the microneedle array is composed of biomolecular glass;
[0013] The biomolecule glass is composed of biomolecules, inducers and a trace amount of solvent; the biomolecules are amino acids and their derivatives and / or peptides; the trace amount of solvent means that the content of the solvent in the biomolecule glass is 0.1-5wt%; preferably 0.1-2wt%; the inducer is selected from nucleotides, nucleotide polymers, RNA, DNA and / or pH regulators.
[0014] In a second aspect, a biomolecular glass soluble microneedle is provided, characterized in that the biomolecular glass refers to an amorphous (non-crystalline) biomolecular matrix that forms a thermodynamic liquid, that is, a liquid with extremely high viscosity, corresponding to a physical solid.
[0015] The biomolecular glass is glass in a broad sense, which refers to an amorphous solid structure composed of biomolecules with short-range order and long-range disorder, and the solid structure has a glass transition phenomenon (Tg>0°C).
[0016] Preferably, the Tg range of the biomolecular glass is 0°C <Tg<200℃。
[0017] More preferably, the Tg range of the biomolecular glass is 20°C <Tg<160℃。
[0018] The biomolecular glass has good glass forming ability (GFA), that is, the ratio of Tg (glass transition temperature) / Tm (melting temperature) is distributed between 0.55 and 0.75, preferably, 0.66 to 0.75.
[0019] In a third aspect, a biomolecule glass soluble microneedle is provided, wherein the biomolecule glass is composed of biomolecules, an inducer, and a trace amount of solvent;
[0020] The biomolecules are amino acids and their derivatives and / or peptide therapeutics;
[0021] The amino acids include one or more of glycine, alanine, valine, leucine, isoleucine, methionine (methionine), proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine, histidine, selenocysteine and pyrrolysine;
[0022] The derivatives are amino acids or peptides with protecting groups, and the protecting groups include: Trt, Boc, Fmoc, Cbz / Z, Allyl, C2-C18 acyl, benzoyl, naphthoyl, OFm, Otbu, OBzl, OAll, OMe, OEt;
[0023] Preferably, the peptide therapeutic agent has biological and / or pharmacological activity; the peptide therapeutic agent may be a linear peptide, a cyclic peptide, or a peptide derivative or conjugate.
[0024] The peptide therapeutic agents include anti-tumor peptides, cytokine mimetic peptides, cardiovascular peptides, host defense peptides, immunomodulatory peptides, metabolic peptides, antiviral peptides, and diagnostic peptides.
[0025] Exemplary peptide therapeutics include octreotide acetate, lanreotide acetate, teicosin acetate, leuprorelin, buserelin, goserelin, gonadorelin, nafarelin, triptorelin, histrelin, cetrorelin, degarelin, abarelix, octreotide, lutetoxyoctreotide, somatostatin, lanreotide, pasireotide, romidepsin, mifatide, recombinant human insulin, thymopentin, recombinant human interferon, glutathione, teriparatide acetate, semaglutide, One or more of liraglutide, lixisenatide, exenatide, benaglutide, dulaglutide, albiglutide, thymopentin, thymosin, salmon calcitonin, teriparatide, bacitracin, octreotide, caperitide, neuropeptide Y, brain natriuretic peptide (BNP), islet amyloid polypeptide (IAPP), vasoactive intestinal peptide (VIP), nesiritide, eptifibatide, oxytocin, bivalirudin, antiphagocytic peptide, vancomycin, methotrexate, and cyclosporine.
[0026] The introduction of inducers can modulate multiple non-covalent interactions between biomolecules.
[0027] Preferably, the inducing agent is selected from nucleotides, nucleotide polymers, RNA, DNA and / or pH regulators;
[0028] Exemplary nucleotides include, but are not limited to, adenosine-5′-monophosphate (AMP), nicotinamide mononucleotide, guanosine-5′-monophosphate (GMP), uridine-5′-monophosphate (UMP), cytidine-5′-monophosphate (CMP), and adenosine-3′-monophosphate (3-AMP).
[0029] The pH adjuster is selected from DL-tartaric acid, hydrochloric acid, sulfuric acid, phosphoric acid, lactic acid, lactobionic acid, citric acid, tartaric acid, oxalic acid, DL-malic acid, maleic acid, quinic acid, adipic acid, fumaric acid, hexanoic acid, heptanoic acid, octanoic acid, valeric acid, butyric acid, propionic acid, and glacial acetic acid, preferably citric acid, nucleotides, and malic acid.
[0030] The solvent is water or physiological saline, and the mass percentage of the solvent is between 0 and 5%, preferably 0 to 2%.
[0031] In a fourth aspect, a biomolecule glass soluble microneedle is provided, characterized in that the biomolecule glass microneedle exhibits excellent mechanical and processing properties. Considering the skin permeability of the glass soluble microneedle, the glass microneedle tip has a hardness greater than 50 MPa and an elastic modulus greater than 1 GPa, facilitating smooth skin penetration.
[0032] In a fifth aspect, a biomolecule glass soluble microneedle is provided, characterized in that the substrate of the biomolecule glass soluble microneedle can be made of biomolecule glass and / or polymer excipients.
[0033] Wherein, the polymer excipient is one or more of hydroxypropyl cellulose, alginic acid, methyl cellulose, chitosan, tragacanth gum, propylene glycol alginate, maltose, hyaluronic acid, chitosan, polyvinyl alcohol, chondroitin sulfate, polyvinyl pyrrolidone, trehalose, dextran, polylactic acid, carrageenan, cellulose acetate, hydroxyethyl methyl cellulose, ethyl hydroxy cellulose, sucrose and carboxymethyl cellulose, poly-γ-glutamic acid, pullulan, gelatin, polydopamine and polyacrylamide.
[0034] In a sixth aspect, a method for preparing biomolecule glass soluble microneedles is provided, the preparation method comprising the following steps:
[0035] (1) Preparation of biomolecular glass by hydrothermal method: a certain amount of biomolecular raw materials are dissolved in water or a mixed solvent, an appropriate amount of inducing agent is added and the pH of the solution system is controlled; a constant temperature is maintained during the hydrothermal method, and the constant temperature time is controlled to achieve step-by-step evaporation of the solvent to obtain biomolecular glass;
[0036] (2) After preheating the biomolecule glass, a microneedle array is prepared by casting, stretching, atomization spraying, microfluidics, or 3D printing;
[0037] (3) Finally, the microneedle substrate is formed by pouring and degassing on the basis of the microneedle array.
[0038] In the above step (1), the pH of the system is adjusted to 1 to 9, preferably 3 to 7;
[0039] The constant temperature is 20-120°C, preferably 40-100°C;
[0040] The constant temperature time is 5 minutes to 6 hours, preferably 30 minutes to 3 hours;
[0041] The preheating temperature is 20-200°C, preferably 40-160°C, and more preferably 40-100°C.
[0042] In a seventh aspect, in certain embodiments, the process of preparing biomolecular glass by a hydrothermal method can be combined with the casting method of preparing microneedles, that is, prepared by the following steps:
[0043] (1) preparing a microneedle pre-casting solution: dissolving the biomolecule raw material in water or a mixed solvent, adding an appropriate amount of an inducer, and regulating the pH of the solution system;
[0044] (2) pouring the above-mentioned pre-casting liquid into the microneedle mold and performing a degassing treatment;
[0045] (3) After drying and demoulding, microneedles are obtained.
[0046] The perfusion method includes but is not limited to self-leveling, high-pressure injection, and microfluidics.
[0047] The degassing method includes but is not limited to centrifugation, decompression or vacuum adsorption.
[0048] The drying conditions in step (3) are: temperature 20-100° C., relative humidity 1-60%, and drying time of more than 2 hours; more preferably 20-50° C., relative humidity 1-30%, and drying time of more than 2 hours.
[0049] In the eighth aspect, when the prepared microneedle substrate is a polymer excipient, the preparation step (3) of the biomolecule glass soluble microneedle prepared as described in the sixth aspect is improved as follows:
[0050] (3) preparing a polymer excipient solution and pouring it onto the biomolecule glass microneedle array prepared in step (2) to form a microneedle substrate.
[0051] In the ninth aspect, the preparation method of the biomolecule glass soluble microneedles as described in the seventh and eighth aspects can also be combined with other conventionally known preparation processes to prepare multilayer microneedles, bubble microneedles, porous microneedles and other types.
[0052] The physical shape and size of the biomolecule glass soluble microneedles of the present invention are not particularly limited, and any conventionally known size may be used.
[0053] For example, the height of the soluble microneedle body can be 100 to 1000 microns, and the angle of the needle tip can be 30 to 40 degrees.
[0054] The dried and peeled biomolecule glass soluble microneedles can be further cut into the shape of patches and / or further lined with an adhesive support for use.
[0055] In the tenth aspect, the biomolecular glass soluble microneedle as described above can be loaded with other active substances during the preparation process, and the active substances can be loaded on the microneedle array and / or substrate of the microneedle; when the active substance is loaded on the microneedle array, its mass accounts for less than 5% of the microneedle array; when the active substance is loaded on the microneedle array and the substrate, its mass accounts for less than 10% of the total mass.
[0056] The active substances include but are not limited to analgesics, neurological drugs, anti-allergic drugs, anti-anxiety drugs, anti-inflammatory drugs, small molecule drugs, and biomacromolecule drugs such as antigen peptides, peptide vaccines, and monoclonal antibodies. Exemplary small molecule drugs include lidocaine, fentanyl, aspirin, ibuprofen, cetirizine, loratadine, rofecoxib, celecoxib, diclofenac sodium, pipotiazide, perphenazine, chlorpromazine, fluphenazine decanoate, thioridazine, sulpiride, penfluridol, clozapine, risperidone, olanzapine, clomipramine, amitriptyline, doxepin, fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, carbamazepine, sodium valproate, magnesium salicylate, sodium salicylate, diflunisal (diflunisal), disalsalate, naproxen, fenbufen, sulindac, piroxicam, celecoxib, choline magnesium salicylate, acetaminophen, indomethacin, naproxen, naproxen, diclofenac, nimesulide, ibuprofen, and voltaren. Exemplary macromolecule drugs include therapeutic cancer vaccines, anthrax vaccines, influenza vaccines, Lyme disease vaccines, rabies vaccines, measles vaccines, mumps vaccines, varicella vaccines, smallpox vaccines, hepatitis vaccines, hepatitis A vaccines, hepatitis B vaccines, hepatitis C vaccines, pertussis vaccines, rubella vaccines, diphtheria vaccines, encephalitis vaccines, Japanese encephalitis vaccines, respiratory syncytial virus vaccines, yellow fever vaccines, polio vaccines, herpes vaccines, human papillomavirus vaccines, rotavirus vaccines, pneumococcal vaccines, meningitis vaccines, pertussis vaccines, tetanus vaccines, typhoid vaccines, cholera vaccines, tuberculosis vaccines, severe acute respiratory syndrome (SARS) vaccines, HSV-1 vaccines, HSV-2 vaccines, HIV vaccines, and combinations thereof.
[0057] On the eleventh aspect, an application of biomolecular glass soluble microneedles is provided, characterized in that the glass soluble microneedles can be used to pierce the skin and / or mucous membranes, blood-eye barrier, blood-brain barrier, etc., for pharmaceutical or aesthetic purposes.
[0058] The pharmaceutical use refers to a bioactive molecule delivery platform, a biosensor or a stimulus-responsive delivery system.
[0059] The aesthetic use is to exfoliate or improve the appearance, smoothness or brightness of the skin.
[0060] In the present invention, terms such as "a", "an" and "the" do not refer to only a single entity, but include general categories, specific examples of which may be used for illustration. The terms "a", "an" and "the" can be used interchangeably with the term "at least one". The phrases "at least one" and "including at least one" followed by a list refer to any one item in the list and any combination of two or more items in the list. Unless otherwise indicated, all numerical ranges include their endpoints and non-integer values between the endpoints.
[0061] In the present invention, the terms "microneedle", "microneedle array" or "microneedle array" refer to structures related to an array that can pierce the stratum corneum to facilitate transdermal delivery of bioactive molecules to the skin. In many cases, they can be used interchangeably.
[0062] The biomolecule glass microneedles provided by the present invention have the following significant advantages:
[0063] (1) The biomolecular glass microneedle body of the present invention is constructed from the therapeutic agent itself and is completely absorbable and usable by the body without generating any metabolic burden;
[0064] (2) The therapeutic agent in the biomolecular glass microneedle of the present invention has high photostability and thermal stability, which is conducive to long-term storage and application of the therapeutic agent;
[0065] (3) The microneedles of the present invention have a large loading capacity and can quickly release biomolecules, effectively improving the bioavailability of biomolecules;
[0066] (4) The biomolecular glass microneedle preparation process of the present invention is simple, green and environmentally friendly, has high batch reproducibility, and is suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0067] FIG1 is a photograph of the thymopentin glass in Example 1;
[0068] FIG2 is a photograph of the vancomycin glass in Example 2;
[0069] FIG3 is a photograph of the soluble glass microneedles prepared in Example 3 (left) and Example 5 (right);
[0070] FIG4 is a photograph of the soluble glass microneedles prepared in Example 4;
[0071] FIG5 is a photograph of the soluble glass microneedles prepared in Example 6 (left) and Example 7 (right);
[0072] FIG6 is a photograph of the soluble glass microneedles prepared in Example 8 (left) and Example 9 (right);
[0073] FIG7 is a scanning electron micrograph of the soluble glass microneedles prepared in Example 10 (left) and Example 11 (right);
[0074] FIG8 is a microscope photograph of the soluble glass microneedles prepared in Example 10 (left) and Example 11 (right);
[0075] FIG9 is a photograph of the soluble glass microneedle piercing the sealing film prepared in Example 10;
[0076] FIG10 is a photograph of the soluble glass microneedles prepared in Example 1 piercing fresh pig ear skin;
[0077] FIG11 is an in vivo pharmacodynamic evaluation of the thymopentin-soluble glass microneedles in rats in Example 1;
[0078] FIG12 is an evaluation of the glucose control effect of the insulin-soluble glass microneedles prepared in Example 9;
[0079] FIG13 is a curve showing changes in neurological function scores of different groups in autoimmune encephalomyelitis (EAE) mice over time;
[0080] FIG14 shows the release curves of the drug-loaded microneedles of Example 19 and Example 20. DETAILED DESCRIPTION
[0081] The present invention will be described in further detail below with reference to the embodiments and drawings, but the embodiments of the present invention are not limited thereto.
[0082] Microneedle mold and material source
[0083] The PDMS microneedle negative mold in the present invention was purchased from Taizhou Microchip Pharmaceutical Technology Co., Ltd. The active parts of the microneedle array include two types: cones and square pyramids, with a height of about 300 or 600 microns and an aspect ratio of about 2:1. The microneedles are arranged in a square pattern consisting of about 10*10 microneedles, with an equal spacing of 500-600um between each microneedle. The reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased through regular channels. If the specific technology or conditions are not indicated in the examples, the technology or conditions described in the literature in this field or the product instructions shall be followed.
[0084] In the following examples, the solvent content in the obtained glass was measured by thermogravimetric analysis.
[0085] Preparation of biomolecule-soluble glass microneedles
[0086] Example 1
[0087] 100 mg of thymopentin powder was weighed and added to 10 mL of ultrapure water to obtain a thymopentin solution; after adding 20 mL of 0.01 M citric acid aqueous solution, the pH of the system solution was measured to be 6.0; the above solution system was heated to 50°C at a heating rate of 10°C / min and kept at this temperature for 1 hour to volatilize the solvent. When the solvent content was less than 2%, a thymopentin glass was obtained;
[0088] The obtained thymopentin glass is shown in Figure 1. As shown in the figure, the thymopentin glass has glass properties and shows good transparency and tensile processing properties.
[0089] The thymopentin glass was preheated at 60°C and poured into the PDMS microneedle negative mold, filling the needle tip and base of the microneedle mold; the mold was centrifuged at 3000 rpm for 5 minutes to degas, and the mold was cooled. After the microneedle body was solidified, the microneedle glass was demolded to obtain thymopentin-soluble glass microneedles.
[0090] Example 2
[0091] 100 mg of vancomycin powder was weighed and added to 20 mL of ultrapure water and 1 mL of glycerol to obtain a vancomycin solution. After adding 10 mL of 0.01 M aqueous hydrochloric acid, the pH of the solution was measured to be 4.0. The solution was heated to 60°C at a heating rate of 10°C / min and kept at this temperature for 3 hours to evaporate the solvent. When the solvent content was less than 1%, vancomycin glass was obtained. The obtained vancomycin glass is shown in Figure 2.
[0092] The vancomycin glass was preheated at 60°C and poured into the PDMS microneedle negative mold, filling both the tip and base of the microneedle mold. The mixture was centrifuged at 2000 rpm for 5 minutes to degas, and the mold was cooled. After the microneedle body solidified, the microneedle glass was demolded to obtain vancomycin-soluble glass microneedles.
[0093] Example 3
[0094] 500 mg of L-histidine powder was weighed and added to 20 mL of ultrapure water and 1 mL of ethanol to obtain a histidine solution. 10 mL of 0.01 M aqueous hydrochloric acid was added, and the pH of the solution was measured to be 5.0. The solution was heated at a heating rate of 50°C / min to 100°C and maintained at this temperature for 0.5 h to evaporate the solvent. When the solvent content was less than 3%, histidine glass was obtained.
[0095] The above-mentioned histidine glass was preheated at 60°C and poured into the PDMS microneedle female mold, filling the needle tip and base of the microneedle mold; rapid decompression was performed under a vacuum pump for 10 minutes to degas, and the mold was cooled to room temperature. After the microneedle body was solidified, the microneedle glass was demolded to obtain histidine-soluble glass microneedles.
[0096] The obtained histidine-soluble glass microneedles are shown in FIG3 (left).
[0097] Example 4
[0098] 100 mg of aspartic acid powder was weighed and added to 20 mL of ultrapure water and 1 mL of glycerol to obtain an aspartic acid solution. 10 mL of 0.01 M aqueous hydrochloric acid was added, and the pH of the solution was measured to be 4.0. The solution was then heated at a heating rate of 10°C / min to 60°C and maintained at this temperature for 3 hours to evaporate the solvent. When the solvent content was less than 1%, an aspartic acid glass was obtained.
[0099] After preheating the aspartic acid glass at 80°C, it was poured into a PDMS microneedle mold, filling both the tip and base. Degassing was performed by centrifugation at 2000 rpm, and the mold was cooled. After the microneedle bodies solidified, the glass was demolded to obtain aspartic acid-soluble glass microneedles. The resulting aspartic acid-soluble glass microneedles are shown in Figure 4.
[0100] Example 5
[0101] 20 mg of tuftsin powder was weighed and added to 20 mL of ultrapure water to obtain a tuftsin solution. 10 mL of 0.01 M malic acid aqueous solution was added, and the pH of the solution was measured to be 6.0. The solution was heated at a heating rate of 10°C / min to 60°C and maintained at this temperature for 2 hours to evaporate the solvent. When the solvent content was less than 1%, a tuftsin glass was obtained.
[0102] The tuftsin glass was preheated at 50°C and poured into a PDMS microneedle negative mold. The mold was centrifuged at 2000 rpm for 5 minutes to degas. The mold was cooled and, after the microneedle body solidified, the microneedle glass was demolded to obtain tuftsin-soluble glass microneedles.
[0103] The obtained histidine-soluble glass microneedles are shown in FIG3 (right).
[0104] Example 6
[0105] 10 mg of semaglutide powder was weighed and added to 20 mL of ultrapure water and 1 mL of glycerol to obtain a semaglutide solution; after adding 10 mL of 0.01 M hydrochloric acid aqueous solution, the pH of the system solution was measured to be 4.0; the above solution system was heated to 60°C at a heating rate of 10°C / min and kept at this temperature for 0.5 h to volatilize the solvent. When the solvent content was less than 1%, a semaglutide glass was obtained;
[0106] After preheating the above-mentioned semaglutide glass at 60°C, it was filled into the PDMS microneedle female mold through microfluidics, filling only the needle tip part of the microneedle mold; degassing was performed by centrifugation at 2000 rpm for 5 minutes, and the mold was cooled. After the microneedle tip part was solidified, a 5% polyvinyl pyrrolidone solution was poured into the base part of the PDMS microneedle mold and degassing was performed by centrifugation at 2000 rpm for 5 minutes; further, the temperature was 60°C and the relative humidity was 50% for 6 hours; after solidification, the microneedle glass was demolded to obtain semaglutide soluble glass microneedles.
[0107] The obtained semaglutide soluble glass microneedles are shown in Figure 5 (left).
[0108] Example 7
[0109] 20 mg of methotrexate powder was weighed and added to 20 mL of ultrapure water to obtain a methotrexate solution; 10 mL of 0.01 M aqueous citric acid solution was added, and the pH of the solution was measured to be 3.0; the solution was heated to 60°C at a heating rate of 10°C / min and kept at this temperature for 2 hours to evaporate the solvent. When the solvent content was less than 1%, a methotrexate glass was obtained;
[0110] The above-mentioned methotrexate glass was preheated at 50°C and poured into the PDMS microneedle female mold, filling only the needle tip part of the microneedle mold; the solution was centrifuged at 2000 rpm for 5 minutes to degas, and the mold was cooled. After the microneedle tip part was solidified, a 5% hyaluronic acid solution was poured into the base part of the PDMS microneedle mold and centrifuged at 2000 rpm for 5 minutes to degas; further, the solution was dried at 80°C and 30% relative humidity for 6 hours; after solidification, the microneedle glass was demolded to obtain methotrexate-soluble glass microneedles.
[0111] The obtained methotrexate-soluble glass microneedles are shown in FIG5 (right).
[0112] Example 8
[0113] 20 mg of cyclosporin powder was weighed, 20 mL of ultrapure water and 1 mL of ethanol were added to obtain a cyclosporin solution; 10 mL of a 0.01 M aqueous lactobionic acid solution was added, and the pH of the solution was measured to be 6.0; the solution was heated at a heating rate of 10°C / min to 100°C and maintained at this temperature for 2 hours to evaporate the solvent. When the solvent content was less than 1%, a cyclosporin glass was obtained;
[0114] The cyclosporin glass was preheated at 120° C. and poured into a PDMS microneedle negative mold, filling only the microneedle mold tip. The mixture was centrifuged at 2000 rpm for 5 minutes to degas. The mold was cooled and the microneedle tip was solidified. A 5% polyvinyl alcohol solution was poured into the base of the PDMS microneedle mold and centrifuged at 2000 rpm for 5 minutes to degas. The mixture was further dried at 80° C. and 50% relative humidity for 6 hours. After solidification, the microneedle glass was demolded to obtain cyclosporin soluble glass microneedles.
[0115] The obtained cyclosporine-soluble glass microneedles are shown in FIG6 (left).
[0116] Example 9
[0117] 10 mg of recombinant human insulin powder was weighed and added to 20 mL of normal saline to obtain a recombinant human insulin solution. After adding 10 mL of 0.01 M adenosine 5′-monophosphate (AMP) aqueous solution, the pH of the solution was measured to be 7.0. The solution was heated at a heating rate of 10°C / min to 40°C and kept at this temperature for 6 hours to evaporate the solvent. When the solvent content was less than 1%, a recombinant human insulin glass was obtained.
[0118] The recombinant human insulin glass was preheated at 40°C and poured into a PDMS microneedle female mold, filling both the tip and base of the microneedle mold. The mold was centrifuged at 2000 rpm for degassing, and the mold was cooled. After the tip of the microneedle was solidified, a 5% solution of hydroxypropyl methylcellulose was poured into the base of the PDMS microneedle mold and centrifuged at 2000 rpm for 5 minutes for degassing. The mold was further dried at 30°C and a relative humidity of 1% for 12 hours. After solidification, the microneedle glass was demolded to obtain recombinant human insulin soluble glass microneedles.
[0119] The obtained recombinant human insulin soluble glass microneedles are shown in Figure 6 (right).
[0120] Example 10
[0121] 100 mg of arginine powder was weighed and added to 20 mL of ultrapure water to obtain an arginine solution. After adding 10 mL of 0.01 M citric acid aqueous solution, the pH of the solution was measured to be 5.0. The solution was heated at a heating rate of 10°C / min to 120°C and kept at this temperature for 1 hour to evaporate the solvent. When the solvent content was less than 1%, arginine glass was obtained.
[0122] The above-mentioned arginine glass was preheated at 120°C and poured into the PDMS microneedle female mold, filling the needle tip and base of the microneedle mold; centrifugal degassing was performed at a speed of 2000 rpm, and the mold was cooled. After the microneedle body was solidified, the microneedle glass was demolded to obtain arginine-soluble glass microneedles.
[0123] The morphology of the obtained arginine-soluble glass microneedles was observed macroscopically using a 3D microscope and microscopically using a scanning electron microscope (SEM). The results are shown in Figures 7 (left) and 8 (left).
[0124] Example 11
[0125] The arginine-soluble glass microneedles in Example 10 can also be prepared by combining the hydrothermal process for preparing biomolecular glass with the casting process for preparing microneedles, that is, by the following steps:
[0126] Weigh 100 mg of arginine powder and add it to 20 mL of ultrapure water to obtain an arginine solution. After adding 10 mL of 0.01 M citric acid aqueous solution, the pH of the system solution was measured to be 5.0.
[0127] After pouring the pre-arginine-citric acid mixture into a PDMS microneedle mold, the mold was heated to 120°C at a rate of 10°C / min and held at this temperature for 1 hour to evaporate the solvent. The mold was then centrifuged at 2000 rpm to degas, and cooled. After the microneedle bodies solidified, the microneedle glass was demolded to obtain arginine-soluble glass microneedles.
[0128] The morphology of the obtained arginine-soluble glass microneedles was observed macroscopically using a 3D microscope and microscopically using a scanning electron microscope (SEM). The results are shown in Figures 7 (right) and 8 (right).
[0129] Scanning electron microscopy and optical microscopy images of arginine-soluble glass microneedles demonstrate that the preparation methods of Examples 10 and 11 both yielded soluble glass microneedles with intact tips. Macroscopic and microscopic images demonstrate that the microneedles, whether conical or square-pyramidal, exhibited excellent shape and sharpness, consistent with the PDMS mold design.
[0130] Example 12 Elastic modulus and hardness of biomolecule-soluble glass microneedles
[0131] The elastic modulus and hardness of the biomolecule-soluble glass microneedles were measured using a nanoindenter (Nano Indenter G200, Agilent). The results are shown in Table 1. The results show that the biomolecule-soluble glass microneedles prepared in Examples 1-11 all have excellent elastic modulus and high hardness, laying the foundation for their further skin penetration applications.
[0132] Example 13: Evaluation Experiment of the Puncture Performance of Biomolecule-Soluble Glass Microneedles
[0133] The puncture performance of the soluble microneedles was measured using the Parafilm M Laboratory Film puncture method. Eight layers of Parafilm were affixed to a foam board to simulate artificial skin. The prepared soluble microneedles were then inserted into the artificial skin using a dispenser. The results, shown in Figure 9, show that the Parafilm was completely punctured, with no breakage at the needle tips. The punctured Parafilm was placed under a microscope, the number of puncture holes observed, and the penetration depth calculated (depth = ∑D × a / A, where a is the number of holes; A is the total number of microneedles; and D is the thickness of a single Parafilm layer, 125 μm). The results are listed in Table 1. The tip lengths of Examples 1, 2, and 11 were 600 μm, while the tip lengths of the remaining glass microneedles were 300 μm. The results demonstrate that the biomolecule-soluble glass microneedles in each example exhibited excellent puncture performance.
[0134] Table 1: Strength test and penetration depth of biomolecule-soluble glass microneedles
[0135] Example 14 Fresh pigskin puncture test method
[0136] Fresh 800 μm thick pig ear skin was selected and the soluble microneedles prepared in Example 1 were inserted into the pig ear skin using an applicator. The results are shown in Figure 10. Clear microneedle holes are visible on the pig ear skin, and the number and arrangement of the holes are consistent with the microneedle array, indicating that the microneedles have sufficient mechanical properties to penetrate the ex vivo pig skin.
[0137] Example 15 Evaluation of the Stability of Biomolecules in Glass Microneedles
[0138] The microneedle array prepared in Example 9 was placed in a storage chamber maintained at 40°C and 96% relative humidity (RH) together with an equivalent amount of insulin solution. After storage in the chamber for 1, 3, 7, and 14 days, the insulin content of the microneedle array was measured. At the specified time points, the array was removed from the chamber and cleaned with 0.1 mol / L acetic acid (1 mL) to obtain an insulin solution. The insulin content of the resulting washing solution was analyzed using a high performance liquid chromatography (HPLC) method. The stability of insulin in the prepared microneedles was compared and analyzed by measuring the insulin solution under the same storage conditions as a reference. By measuring the peak area of insulin in the selected samples and dividing it by the peak area of insulin initially measured, the percentage of undegraded insulin remaining in the microneedles or solution at each time point was determined. The results are listed in Table 2.
[0139] The above results show that in the 14-day accelerated stability experiment, the stability of insulin in the glass microneedles is significantly better than that in the solution group, indicating that the prepared soluble glass microneedles can effectively protect the activity of bioactive molecules and facilitate long-term storage.
[0140] Evaluation of the efficacy of biomolecules in glass microneedles
[0141] Example 16 Evaluation of the glucose control effect of the recombinant human insulin soluble glass microneedles prepared in Example 9
[0142] The spontaneous type i diabetes model mice (male, 8 weeks old) ordered are divided into three groups, 6 in each group. The experimental group mice are administered through the skin by glass microneedles, and the dosage is 4IU / Kg. The blank group mice are not treated, and the control group mice are injected with recombinant insulin by tail vein, and the dosage is 4IU / Kg. The blood glucose concentration is measured at different time points. The tail blood of the mice is taken every hour, and the fasting blood glucose value of the mice is measured with a blood glucose meter. The horizontal axis is time, and the vertical axis is the fasting blood glucose value of the experimental mice. The result is shown in Figure 11. To the regulation curve of the blood glucose of spontaneous type i diabetes mice, it is confirmed that the recombinant human insulin soluble glass microneedle prepared in Example 9 can effectively control the blood glucose of mice, and is more stable than the injection of insulin to control the blood glucose effect.
[0143] Example 17 Pharmacodynamic Evaluation of Thymopentin Soluble Glass Microneedles in Rats
[0144] Experimental Methods: 28 SPF-grade male SD rats, weighing 180-220 g, were used. They had not taken any other medications prior to the experiment. Thymopentin powder was dissolved in physiological saline to prepare a thymopentin solution, which served as a reference preparation. The test preparation was the thymopentin-soluble glass microneedles prepared in Example 1. The 28 SD rats were randomly divided into four groups, designated Groups 1 to 4, with seven rats in each group, for in vivo pharmacodynamic studies.
[0145] Before the experiment began, an immunosuppressive model was established. The immunosuppressant cyclophosphamide powder was purchased from Jiangsu Hengrui Medicine Co., Ltd. and prepared into a 1 mg / L cyclophosphamide solution with normal saline. Except for Group 1, the remaining three groups of rats received an intraperitoneal injection of the immunosuppressant at a dose of 35 mg / kg / day for three consecutive days to suppress the rats' immune function. Group 1 served as a blank control group and received an intraperitoneal injection of 35 mL / kg of normal saline.
[0146] After the model was successfully established after three days of continuous injection, a pharmacodynamic evaluation was performed. The first group of rats served as a blank control group and the second group of rats served as a negative control group. They all received subcutaneous intravenous injections of 1 mL / kg of normal saline for seven consecutive days. The third group of rats served as a positive control group and received a subcutaneous injection of thymopentin solution at a dose of 100 ug / kg. The fourth group of rats was given the thymopentin soluble glass microneedles prepared in Example 1 at a dose of 100 ug / kg for seven consecutive days. The three groups of rats were then killed by cervical dislocation, and the thymus and spleen of each rat were collected, weighed, and the organ coefficient was calculated. The calculation formula of the organ coefficient (Organ index) is as follows:
[0147] Where W0 is the mass of the thymus or spleen, and W is the weight of the rat. As shown in Figure 12, the spleen and thymus coefficients in Group 2 of the negative control group were lower than those in Group 1 of the blank control group, confirming the successful establishment of the immunosuppressive model. The spleen and thymus coefficients in Groups 3 and 4 of the drug-treated group were higher than those in the negative control group of the model group, demonstrating statistically significant improvements in the organ coefficients of the immunosuppressed rats. This confirms that the thymopentin-soluble glass microneedles are more effective than the solution formulation.
[0148] Example 18 Neurological function scores of the microneedles prepared in Example 5 in autoimmune encephalomyelitis (EAE) mice
[0149] Specifically, the EAE group was treated with 200 μg of MOG35-55 dissolved in 200 μl of PBS buffer and then thoroughly mixed with 200 μl of Freund's complete adjuvant (CFA) to form an emulsion (the final concentration of inactivated tuberculin bacilli was 5 mg / mL). The normal control group was treated with 200 μl of PBS and 200 μl of CFA. 200 μg of the emulsion was subcutaneously injected at two points on the back of the mouse. 500 ng of pertussis toxin was injected intraperitoneally at 0 and 48 hours after immunization. On the first day after the EAE model was established, the mouse was subcutaneously administered with a glass microneedle at a dose of 100 μg / kg for 7 consecutive days. This was designated as the glass microneedle intervention group.
[0150] Neurological function scores of experimental mice in each group were scored daily after immunization and observed for 30 consecutive days. Neurological function scores were calculated according to the following criteria: 0: no symptoms; 1: decreased tail tone (complete weakness, inability to curl the tail tip) or hindlimb weakness (unsteady gait); 2: tail and hindlimb weakness; 3: hindlimb paralysis (unilateral or bilateral hindlimb movement to a certain extent); 4: complete hindlimb paralysis (complete inability to move the hindlimbs or forelimbs dragging the hindlimbs); 5: death.
[0151] The results are shown in FIG13 . The neurological function score results in EAE mice indicate that the tuftsin-soluble glass microneedles prepared in Example 5 can effectively repair the neurological function in EAE mice.
[0152] Example 19
[0153] As described in the tenth aspect, the microneedles provided by the present invention can also be loaded with active drugs for rapid and convenient transdermal drug delivery. The specific method is as follows: 100 mg of arginine powder and 0.5 mg of lidocaine hydrochloride powder are weighed and added to 20 mL of ultrapure water to obtain an arginine-lidocaine solution; after adding 10 mL of 0.01 M citric acid aqueous solution, the pH of the system solution is measured to be 5.0;
[0154] After pouring the mixed solution into a PDMS microneedle mold, the mold was heated to 40°C at a rate of 10°C / min and held at this temperature for 12 hours to evaporate the solvent. The mold was then centrifuged at 2000 rpm to degas, and cooled. After the microneedle bodies solidified, the microneedle glass was demolded to obtain arginine-lidocaine soluble glass microneedles.
[0155] Example 20
[0156] Weigh 100 mg of arginine powder and 0.2 mg of loratadine and add them to 20 mL of ultrapure water to obtain an arginine-loratadine solution. After adding 10 mL of 0.01 M citric acid aqueous solution, the pH of the system solution was measured to be 5.0.
[0157] After pouring the mixed solution into a PDMS microneedle mold, the mold was heated to 40°C at a rate of 10°C / min and held at this temperature for 12 hours to evaporate the solvent. The mold was then centrifuged at 2000 rpm to degas, and cooled. After the microneedle bodies solidified, the microneedle glass was demolded to obtain arginine-loratadine soluble glass microneedles.
[0158] Example 21 Determination of the release curve of drug-loaded soluble microneedles.
[0159] To determine the in vitro drug release kinetics of the prepared drug-loaded microneedles, the drug-loaded microneedles prepared in Examples 19 and 20 were encapsulated in a dialysis bag (molecular weight cutoff: 3 kDa) and then immersed in phosphate buffered saline (PBS, pH 7.4) at 37°C. The drug-loaded microneedles dissolved in the dialysis bag, and the drug was released into the PBS via the bag. Samples were taken at predetermined time points (0.2 mL each time), and an equal amount of PBS solution was added to measure the cumulative drug release rate from the microneedles. The results, shown in Figure 14, show that the cumulative drug release exceeded 80% within 1 hour, demonstrating that the microneedles can rapidly release the loaded drug.
[0160] The applicant states that the present invention is intended to illustrate the detailed methods of the present invention through the above-described embodiments, but the present invention is not limited to the above-described detailed methods, that is, it does not mean that the present invention must rely on the above-described detailed methods in order to be implemented. Those skilled in the art should understand that any improvements to the present invention, equivalent substitutions for various raw materials in the products of the present invention, addition of auxiliary ingredients, and selection of specific methods, etc., are all within the scope of protection and disclosure of the present invention.
Claims
1. A biomolecular glass microneedle, the microneedle comprising a microneedle array and a substrate; wherein at least a portion of the microneedle array is composed of biomolecular glass; The biomolecule glass is composed of biomolecules, inducers and trace amounts of solvents; the biomolecules are amino acids and their derivatives and / or peptides; the trace amounts of solvents refer to solvents whose content in the biomolecule glass is 0.1-5wt%; preferably 0.1-2wt%; the inducers are selected from nucleotides, nucleotide polymers, RNA, DNA and / or pH regulators; the pH regulators are selected from one or more of DL-tartaric acid, hydrochloric acid, sulfuric acid, phosphoric acid, lactic acid, lactobionic acid, citric acid, tartaric acid, oxalic acid, DL-malic acid, maleic acid, quinic acid, adipic acid, fumaric acid, caproic acid, heptanoic acid, caprylic acid, valeric acid, butyric acid, propionic acid and glacial acetic acid.
2. [Corrected 07.06.2023 in accordance with Rule 91] The biomolecular glass microneedle according to claim 1, It is characterized in that The ratio of Tg (glass transition temperature) / Tm (melting point temperature) of the biomolecular glass is distributed between 0.55 and 0.
75.
3. [Corrected 07.06.2023 in accordance with Rule 91] The biomolecular glass microneedle according to claim 1, It is characterized in that The ratio of Tg (glass transition temperature) / Tm (melting point temperature) of the biomolecular glass is distributed between 0.66 and 0.
75.
4. The biomolecular glass microneedle according to claims 1-3, It is characterized in that The solvent is water, physiological saline, or a mixed solvent of water and ethanol, or a mixed solvent of water and glycerol. The proportion of the solvent other than water in the mixed solvent is between 0 and 50 v / v%, preferably 5 to 10 v / v%.
5. The biomolecular glass microneedle according to claims 1-4, It is characterized in that The hardness of the biomolecular glass microneedle is greater than 50MPa, and the elastic modulus of the biomolecular glass microneedle is greater than 1Gpa.
6. The biomolecular glass microneedle according to claims 1-5, It is characterized in that The substrate of the biomolecule glass soluble microneedle may be made of biomolecule glass and / or polymer.
7. The method for preparing the biomolecule glass needle according to claims 1 to 6, It is characterized in that Its preparation comprises the following steps: (1) Preparation of biomolecular glass by hydrothermal method: dissolving a certain amount of biomolecular raw materials in water or a mixed solvent, adding an appropriate amount of inducing agent and adjusting the pH of the solution system; maintaining a constant temperature in the hydrothermal method, adjusting the constant temperature time to achieve step-by-step evaporation of the solvent, and obtaining biomolecular glass; (2) after preheating the biomolecule glass, preparing the microneedle array by casting, stretching, atomization spraying, microfluidics or 3D printing; (3) Finally, pouring and degassing are performed on the basis of the microneedle array to form a microneedle substrate.
8. [Corrected 07.06.2023 according to Rule 91] A method for preparing a biomolecular glass microneedle as claimed in any one of Claims 7, It is characterized in that In the step of preparing biomolecular glass by hydrothermal method, the pH of the system is adjusted to 1-9, preferably, the pH is 3-7; the constant temperature is 20-120°C, preferably 40-100°C; the constant temperature time is 5min-6h, preferably 30min-3h; the preheating temperature is 20-200°C, preferably 40-160°C, more preferably 40-100°C.
9. The method for preparing the biomolecular glass soluble microneedle according to any one of claims 7 to 8, It is characterized in that The pouring method includes self-leveling, high-pressure injection, and microfluidics; the degassing method includes centrifugation, decompression, or vacuum adsorption.
10. Use of the biomolecule glass microneedle according to any one of claims 1 to 6 as a drug carrier or in the preparation of cosmetic products.
Citation Information
Patent Citations
Dry glassy composition comprising a bioactive material
CN102725393A
Process for preparing micro-array drug delivery system of glucagon-like peptide-1 receptor stimulating agent
CN112741798A
Glass based on amino acids as well as preparation method and application thereof
CN113754556A
Cyclic peptide glass and pharmaceutical composition glass containing cyclic peptide
CN114014908A
Semaglutide soluble microneedle patch and preparation method therefor
WO2022152131A1
